PROTARA THERAPEUTICS INC (TARA)
Health Care · Clinical-stage biopharmaceutical / cell and gene therapy · NASDAQ
Clinical-stage biopharmaceutical company developing TARA-002, a cell therapy based on an established immunopotentiator, and IV Choline Chloride for oncology, rare diseases, and nutritional support.
What PROTARA THERAPEUTICS INC does
Protara Therapeutics is a New York City-based clinical-stage biopharmaceutical company developing transformative therapies for cancer and rare diseases. The company is advancing two main programs: TARA-002, an investigational cell therapy derived from OK-432 (a broad immunopotentiator originally approved in Japan and Taiwan), which is being explored in non-muscle invasive bladder cancer and lymphatic malformations; and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition support. The company has not yet generated any revenue and does not expect to do so in the near term.
Themes: ["cancer immunotherapy"]
Fundamentals
- Price$4.20 as of 2026-07-09 close
- Market cap$236M as of 2026-07-10
- 1-year return+30.4% as of 2026-07-09 close
- Net margin-113.2% as of 2026-07-10
- ROE-38.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.51 as of 2026-07-10
Key risks (from latest filing)
["Limited operating history with no revenue generation; company has never completed registrational clinical trials or commercialized any product, creating uncertainty about ability to successfully develop and bring products to market."]
Competitors & peers
- Cellular immunotherapy companies developing cancer cell therapies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.